-36%

est. 2Y upside i

HealthcareSeries B

Stedi is the only programmable healthcare clearinghouse. We bring best-in-class software standards to healthcare transactions: fast APIs, reliable connections, scalable architecture, meticulous engineering. No compromises.

Rank

#888

Sector

Healthcare Technology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Stedi presents a moderate upside opportunity for a job seeker.

Last updated: March 10, 2026

Bull (35%)+250%

Stedi's AI-enabled clearinghouse rapidly captures significant market share from legacy incumbents like Change Healthcare, driving revenue to over $100M by 2028. This strong performance, coupled with network effects and high switching costs, justifies a premium valuation of 17x revenue, leading to a $1.7B+ exit and substantial returns for common shareholders.

Base (40%)+50%

Stedi continues its strong growth in the healthcare clearinghouse market, reaching approximately $70M in revenue by 2028. Competitive pressures from established players like SPS Commerce and Boomi in the broader B2B integration market lead to a valuation multiple of 10-11x revenue, resulting in a $700M-$800M exit and moderate returns for common shareholders.

Bear (25%)-60%

Slower than anticipated adoption of AI-enabled clearinghouse solutions and aggressive modernization efforts by incumbents like Optum (Change Healthcare) limit Stedi's market penetration. Revenue growth stalls at $40M by 2028, and a valuation multiple contraction to 5x revenue results in a $200M exit, wiping out most common stock value due to the $142M liquidation preference.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors hold $142M in liquidation preferences ahead of common stock. In an exit at the estimated current valuation of $495M, $142M would go to preferred shareholders first, leaving $353M for common shareholders.

Dilution Risk

moderate

As a Series B company, Stedi will likely require at least one or two more significant funding rounds before an IPO or acquisition, leading to further dilution for existing common shareholders.

Secondary Liquidity

limited

Secondary liquidity for a Series B company is typically limited, with no active public market for shares, though occasional tender offers or private sales might occur.

Engineering — 7 roles

Sales — 7 roles

Business — 5 roles

Strategy & Operations — 5 roles

View all 24 open roles at Stedi →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Stedi's data — designed to show you've done your homework.

  • 1

    “How is Stedi planning to further leverage its 'AI-enabled clearinghouse' capabilities to capture market share, particularly as incumbents like Optum (Change Healthcare) potentially modernize their offerings?”

  • 2

    “Given the estimated $33M in revenue and the large $1.4B SAM, what are the key strategic initiatives to accelerate market penetration beyond new venture-backed health tech companies and into the broader healthcare and B2B integration markets?”

  • 3

    “With the recent Series B funding and the company's stage, what is the anticipated timeline for a liquidity event, and how does the company plan to manage potential dilution for employees' equity in future funding rounds?”

Community

Valuation Sentiment

Our model estimates -36% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.